Aurigene offer diverse solutions to all your medicinal chemistry research requirements, providing the right blend of innovation, vigour, expertise and thorough knowledge of the various aspects of discovery research. With a very experienced scientific team with a 1:6 PhD to MSc ratio and a leadership team with a collective experience of >200 years, together with our experience in handling complex synthetic chemistry problems and our in-house collection of >50000 chemicals, we are ready to rapidly initiate any chemistry programs from our collaborators. We are well versed in all aspects of medicinal chemistry projects, including novel areas like carbohydrates and steroids, PROTACs and molecular glues, oligonucleotides etc.
With a combination of 600+ highly skilled scientists and a state-of-the-art infrastructure spanned over two sites at Bangalore and Hyderabad, we provide the best-in-class medicinal chemistry services to various biotech, pharmaceutical and agrochemical companies. We offer flexible business models like FFS in addition to the usual FTE mode of collaboration, in addition to offering a variety of mix and match programs like chemistry CRO programs together with DMPK or in vitro Biology programs.
Why Aurigene Pharmaceutical Services?
Multiple design or route options and complete design to delivery support
Capability across wide chemistry platforms
Library synthesis across various platforms
Lab facilities operating from two locations: Hyderabad and Bangalore
Service in all areas of drug discovery and development
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Medicinal Chemistry
Resources
JANUARY 04, 2021
Role of Peptide Synthesis Based Drugs
Amino acids, peptides and proteins play multiple roles in the normal functioning of the body.Group of amino acids between 2 to 50 are called peptides. They often act as hormones and play diverse roles in the normal biological processes in the human body such as metabolism, intercellular signaling and neurotransmission.Peptide synthesis based drug have a high pote...
Read More
Evolution in Pharma Industry and Demand for Integrated CDMO
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....
Read More
Technology meets sustainability - How a complex API development process goes green
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more....
Read More
Construction of a quinoline ring via a 3-component reaction in water: crystal structure analysis and H-bonding patterns of a 2-aryl quinoline
2012
Montmorillonite K-10 mediated green and one-pot synthesis of 2-substituted quinolines has been accomplished via a 3-component reaction of aniline, aldehydes and ethyl 3,3- diethoxypropionate in the presence of air oxygen in water. The crystal structure analysis and H-bonding patterns of one compound prepared are presented. ...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market